Small molecule signal transduction inhibitors for the treatment of solid tumors.
作者： Alexandra Leary , Stephen R. D. Johnston
DOI: 10.1080/07357900701259694
关键词:
摘要: A greater understanding of the pathogenesis malignancy has led to development novel therapies designed target aberrant molecular pathways that characterize and distinguish cancer cells from normal tissue. Small molecules are being interfere with specific steps along deregulated signaling cascade cytoplasmic membrane nucleus. Viable targets include growth factor receptors their downstream second messengers, modulators cell cycle or apoptosis, regulators protein trafficking degradation, transcription regulators. This review will discuss small molecule signal transduction inhibitors in various stages address strategic issues relating clinical trial design these targeted agents.
core.ac.uk
informahealthcare.com参考文章(168)
Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson, Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. ,vol. 10, pp. 361- 369 ,(2003) , 10.1177/107327480301000502
Piotr Smolewski, Tadeusz Robak, Agnieszka Janus, The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cellular & Molecular Biology Letters. ,vol. 10, pp. 479- ,(2005)
Xihong Zhang, Douglas Yee, Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility Cancer Research. ,vol. 62, pp. 4369- 4375 ,(2002)
Yardena Samuels, Victor E. Velculescu, Oncogenic Mutations of PIK3CA in Human Cancers Cell Cycle. ,vol. 3, pp. 1221- 1224 ,(2004) , 10.4161/CC.3.10.1164
George C. Prendergast, Wei Du, Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors Cancer Research. ,vol. 59, pp. 5492- 5496 ,(1999)
Richard Poulsom, Valentine M. Macaulay, Gareth D. H. Turner, David R. Davies, Simon F. Brewster, Giles O. Hellawell, Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persists in Metastatic Disease Cancer Research. ,vol. 62, pp. 2942- 2950 ,(2002)
Edward A. Sausville, Tadashi Igishi, Leticia Quintanilla-Martinez, Adrian M. Senderowicz, Vyomesh Patel, Marcus Kremer, John F. Ensley, J. Silvio Gutkind, Tyler Lahusen, Chidchanok Leethanakul, Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1 Clinical Cancer Research. ,vol. 8, pp. 3549- 3560 ,(2002)
David Solit, Mark M. Moasser, Qing-Bai She, Andrea Basso, Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt Pathway Signaling Clinical Cancer Research. ,vol. 9, pp. 4340- 4346 ,(2003)
R. J. Motzer, B. I. Rini, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. M. Bukowski, D. J. George, S. T. Kim, C. M. Baum, Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology. ,vol. 23, pp. 4508- 4508 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.4508
Kim M. Lonergan, Othon Iliopoulos, Michael Ohh, Takumi Kamura, Ronald C. Conaway, Joan Weliky Conaway, William G. Kaelin, Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 Molecular and Cellular Biology. ,vol. 18, pp. 732- 741 ,(1998) , 10.1128/MCB.18.2.732